Friday, March 31, 2023
News on Pathogens and Preparedness
Global Biodefense
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe
No Result
View All Result
Global Biodefense
No Result
View All Result
Home Featured News

BARDA Conducting Market Research on Ebola Medical Countermeasures

by Global Biodefense Staff
February 23, 2017
BARDA Conducting Market Research on Ebola Medical Countermeasures

The Office of the Biomedical Advanced Research and Development Authority (BARDA) is seeking information on sources for developing and manufacturing Ebola vaccines and therapeutics, specifically vaccines targeting Zaire Ebolavirus.

Infections by Ebola virus result in a highly lethal VHF; mortality has ranged from 25-90 percent depending on the outbreak and the virus species by which it was caused. Medical countermeasures (MCM) against Ebola virus are urgently needed should future outbreaks of this virus occur, similar to the 2014-2015 epidemic in West Africa.

Vaccines

Vaccines at a minimum should have evidence of an active IND with ongoing or completed Phase 2 or 3 clinical studies, non-clinical efficacy in a nonhuman primate model of Ebola infection, and production at the final scale manufacturing process with qualification of any needed release assays.

Any proposed vaccine shall have completed and include appropriate safety, toxicology, and effectiveness profiles to allow continued progress towards approval for Emergency Use Authorization (EUA) through the Animal Rule and, ultimately, approval with a Biologics License Application (BLA).

Other requirements will include a defined regulatory path, cGMP production capabilities and capability to demonstrate consistency of Phase 3 lots.

Therapeutics

Therapeutics at a minimum should have evidence of an active IND, non-clinical efficacy in a nonhuman primate model of Ebola infection, scalable manufacturing with qualification of release assays and safety in humans at the efficacious dose via completion of a Phase I or equivalent clinical study.

Any proposed therapeutic shall have completed and include appropriate safety, toxicology, and effectiveness profiles to allow continued progress towards approval for Emergency Use Authorization through the Animal Rule and, ultimately, approval with a Biologics License Application (BLA). Other requirements will include a defined regulatory path, cGMP production capabilities and capability to demonstrate lot consistency.

BARDA is requesting information on availabilities, capabilities, and other pertinent marketplace data to strengthen BARDA’s understanding of the current and future marketplace.

The information requests are organized by vaccine vs. therapeutics and business size:

  • EBOLA Vaccine (01A) Small Business: BARDA-2017-EBOLA-Vaccine-(01A)
  • EBOLA Vaccine (01B) Other Than Small Business: BARDA-2017-EBOLA-Vaccine-(01B)
  • Ebola Therapeutic (02A) Small Business: BARDA-2017-Ebola-Therapeutic-(02A)
  • Ebola Therapeutic (02B) Other Than Small Business: BARDA-2017-Ebola-Therapeutic-(02B)

The response deadline for each of these opportunities is March 10, 2017 at 12:00 pm Eastern.

Tags: AntiviralsASPRBARDAEbolaHHSRFISelect AgentsVaccines

Related Posts

Medical Countermeasures

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA
Funding News

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023
DARPA Selects Teams to Develop Vaccine Durability Prediction Model
Medical Countermeasures

DARPA Selects Teams to Develop Vaccine Durability Prediction Model

January 13, 2023
small glass vials on an assembly line await filling of vaccine solution
Industry News

Sabin Vaccine Institute to Advance Ebola Sudan and Marburg Vaccines with New BARDA Funding

January 12, 2023
Load More

Latest News

Scientists Design Molecule to Slow SARS-Cov-2 Infection

March 29, 2023

Biodefense Headlines – 26 March 2023

March 26, 2023
Biodefense Headlines – 12 March 2023

Biodefense Headlines – 12 March 2023

March 12, 2023
Partner Therapeutics’ Novel Approach to Stratify Sepsis Patients Gains Backing From BARDA

Biopreparedness Research Virtual Environment (BRaVE) Initiative Backed by $105M DOE Funding

January 25, 2023

Subscribe

  • About
  • Contact
  • Privacy
  • Subscribe

© 2022 Stemar Media Group LLC

No Result
View All Result
  • Featured
  • COVID-19
  • Funding
  • Directory
  • Jobs
  • Events
  • Subscribe

© 2022 Stemar Media Group LLC